Expert Review of Hematology · 2016 · 41 citations · 15 references
MedicineOncologyPharmacotherapyCancer PharmacologyMedical OncologyOncology PharmacotherapyHematologic Malignancy PharmacotherapyHematologic Malignancy TherapyMultiple MyelomaTreatment Sequencing In Immuno-oncologyBortezomib-based RegimensMultiple Myeloma TherapyMultiple Myeloma TreatmentOptimal Treatment DurationOptimal Treatment RegimesRefractory Multiple MyelomaRelapsed Multiple MyelomaTreatment Sequences
BACKGROUND: Evidence supporting optimal treatment sequencing in relapsed/refractory multiple myeloma (RRMM) patients requiring multiple therapy lines is lacking. METHODS: Using retrospective chart data, this study describes real-world RRMM treatment patterns and related progression-free survival (PFS) in US community oncology clinics. RESULTS: Bortezomib ± a non-immunomodulatory drug (IMiD), lenalidomide ± a non-proteasome inhibitor (PI), bortezomib + an IMiD were the most commonly used regimens in early lines of therapy. Median PFS was similar in 1(st) (11.1 months) and 2(nd) line (10.5) and decreased in lines 3 through 5 (3(rd): 7.9; 4(th): 7.2, 5(th): 5.4). Longest PFS (12.5 months) in first line was with bortezomib + ImiD; longest PFS in second line was with lenalidomide ± a non-PI was (13.2 months). CONCLUSIONS: Re-treatment with bortezomib was common; novel agents were reserved for later therapy lines. Overall, the observed PFS associated with real-world treatment sequences were shorter than those reported in clinical trials.
15
The National Comprehensive Cancer Network (NCCN).
Elizabeth H. Wood · Europe PMC (PubMed Central) · 2004 · 2.9K citations · Full text
Improved survival in multiple myeloma and the impact of novel therapies
Shaji Kumar, S. Vincent Rajkumar, Angela Dispenzieri et al. · Blood · 2007 · 2.3K citations · Full text
Medicine, Oncology, Pharmacotherapy +14
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Jens G. Lohr, Petar Stojanov, Scott L. Carter et al. · Cancer Cell · 2014 · 1K citations · Full text
Jesús F. San Miguel, Katja Weisel, Philippe Moreau et al. · The Lancet Oncology · 2013 · 799 citations · Full text
Medicine, Oncology, Pharmacotherapy +12